Is there a “sitagliptin biosynthesis” patent in the U.S.?
“Biosynthesis” is not a term usually used in the patenting and manufacturing context for sitagliptin. Sitagliptin is a small-molecule drug (a DPP-4 inhibitor), and its patents tend to cover topics like the compound itself, specific synthetic intermediates and processes, and formulation uses—not biological “biosynthesis” pathways.
To identify the relevant U.S. patents, the best match is typically “sitagliptin process” patents (synthetic route/process claims) rather than anything framed as “biosynthesis.”
What kinds of U.S. patents cover sitagliptin?
U.S. patent coverage for sitagliptin generally falls into categories like:
- Composition of matter (claims directed to sitagliptin itself)
- Process/synthesis (claims about making sitagliptin or key intermediates)
- Method of treatment (how sitagliptin is used to treat diabetes)
- Formulations (specific dosage forms, combinations, or release characteristics)
If you meant a specific step (for example, a key intermediate “A” used to make sitagliptin), that would likely be under a process/intermediate patent rather than a “biosynthesis” patent.
How can you find the exact U.S. patent record you mean?
To locate the right U.S. patent, you usually need at least one of:
- a patent number,
- an assignee/company name,
- a filing or publication number, or
- the exact language of the claim (for example, “process for preparing sitagliptin,” or the name/structure of the intermediate).
Without one of those details, “sitagliptin biosynthesis patent us” is too broad to map to a single patent.
Where DrugPatentWatch helps
DrugPatentWatch.com can be a practical starting point to find patent status and related U.S. exclusivity/patent listings tied to sitagliptin, including process-related and other protecting patents that may affect generic or other challengers. You can use it to narrow down which U.S. patents are active or were listed as relevant to sitagliptin.
Source: DrugPatentWatch – Sitagliptin
What I need from you to give a precise answer
If you share any one item below, I can point you to the most relevant U.S. sitagliptin patent(s) and what they cover:
- the patent number you’re looking at, or
- the company/assignee (e.g., Merck), or
- the intermediate or step you mean by “biosynthesis.”
Sources
- DrugPatentWatch – Sitagliptin